Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.71 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 3/20 | 0.51 |
| ▸ | CCR3 | P51677 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236282 | 0.85 | DRD2 (0.61) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3289104 | 0.85 | HRH3 (0.68) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL4227255 | 0.83 | HRH3 (0.67) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4233978 | 0.83 | HRH3 (1.00) | HRH3 | |
| SCHEMBL1409317 | 0.82 | SLC6A2 (0.69) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL12377875 | 0.80 | HRH3 (0.54) | HRH3SLC6A2SLC6A3SLC6A4EPHX2 | |
| SCHEMBL6496199 | 0.79 | SLC6A2 (0.66) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL26049997 | 0.79 | SLC6A2 (0.66) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4443660 | 0.79 | HRH3 (0.60) | HRH3MGLLSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL13898673 | 0.79 | HRH3 (0.53) | HRH3SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723331-B2 | Thienopyrimidine compounds and uses thereof | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| EP-2121703-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20080051405-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008020799-A1 | THIENOPYRIMIDIN-4-ONE AND THIENOPYRIDAZIN-7-ONE DERIVATIVES AS MCH RL ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051405-A1 | Therapeutic Agents | GPR119, HTT, IAPP | HRH3 1346/4885MGLL 509/4885SLC6A2 1701/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885MGLL 2765/4885SLC6A2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.